EverSource Wealth Advisors LLC Has $3.36 Million Stock Position in Eli Lilly and Company (NYSE:LLY)

EverSource Wealth Advisors LLC raised its holdings in Eli Lilly and Company (NYSE:LLY) by 4.9% in the third quarter, Holdings Channel.com reports. The fund owned 3,795 shares of the company’s stock after acquiring an additional 177 shares during the quarter. EverSource Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $3,363,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of LLY. Moors & Cabot Inc. boosted its position in Eli Lilly and Company by 2.6% during the third quarter. Moors & Cabot Inc. now owns 21,421 shares of the company’s stock worth $18,978,000 after purchasing an additional 539 shares during the period. Altman Advisors Inc. acquired a new stake in shares of Eli Lilly and Company during the 3rd quarter worth approximately $1,425,000. Glaxis Capital Management LLC acquired a new stake in Eli Lilly and Company during the third quarter worth $443,000. Darwin Wealth Management LLC bought a new stake in Eli Lilly and Company in the third quarter valued at about $378,000. Finally, Anthracite Investment Company Inc. bought a new stake in shares of Eli Lilly and Company in the 3rd quarter valued at approximately $2,215,000. 82.53% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

LLY has been the topic of several analyst reports. Deutsche Bank Aktiengesellschaft lowered their target price on shares of Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating on the stock in a report on Monday, November 4th. Truist Financial boosted their target price on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a “buy” rating in a research report on Thursday, October 10th. Morgan Stanley restated an “overweight” rating and issued a $1,106.00 price objective on shares of Eli Lilly and Company in a report on Tuesday, August 27th. Barclays cut their target price on Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating on the stock in a research note on Thursday, October 31st. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $885.00 price target on shares of Eli Lilly and Company in a research report on Monday, September 16th. Four equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $1,007.94.

Eli Lilly and Company Stock Performance

Shares of LLY traded up $21.38 during mid-day trading on Wednesday, hitting $751.11. 982,328 shares of the company’s stock were exchanged, compared to its average volume of 3,167,271. The company has a quick ratio of 0.97, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. The firm has a market cap of $713.04 billion, a price-to-earnings ratio of 78.88, a price-to-earnings-growth ratio of 2.82 and a beta of 0.43. The stock’s 50-day simple moving average is $875.60 and its 200-day simple moving average is $870.81. Eli Lilly and Company has a 52 week low of $561.65 and a 52 week high of $972.53.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing the consensus estimate of $1.52 by ($0.34). The company had revenue of $11.44 billion during the quarter, compared to analyst estimates of $12.09 billion. Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. Eli Lilly and Company’s revenue was up 20.4% on a year-over-year basis. During the same period in the prior year, the firm earned $0.10 earnings per share. On average, equities research analysts expect that Eli Lilly and Company will post 13.21 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 0.69%. The ex-dividend date is Friday, November 15th. Eli Lilly and Company’s dividend payout ratio is currently 56.22%.

Insider Activity

In other news, CAO Donald A. Zakrowski sold 900 shares of Eli Lilly and Company stock in a transaction on Friday, November 8th. The stock was sold at an average price of $803.38, for a total value of $723,042.00. Following the transaction, the chief accounting officer now owns 5,480 shares in the company, valued at approximately $4,402,522.40. This trade represents a 14.11 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.